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SObjectives: Pleural lavage cytology is the microscopic study of cells obtained from saline instilled into and re-
trieved from the chest during surgery for non–small-cell lung cancer. The aims of this study were to collate multi-
institutional individual patient data for meta-analysis to determine independence as a prognostic marker and to
characterize the impact of positive results on stage-adjusted survival.
Methods: We identified 31 publications from 22 centers/research groups that performed pleural lavage cytology
during surgery for non–small-cell lung cancer and invited submission of individual patient data. Actuarial sur-
vival was calculated using Kaplan-Meier methods, and comparisons were performed using the log-rank test.
Cox proportional hazards regression was used to ascertain the covariates associated with survival.
Results: By January 1, 2008, submissions were received internationally from 11 centers with individual data from
8763 patients. In total, 511 (5.8%) patients had a positive pleural lavage cytology result, and this was shown to be
an independent predictor of adverse survival associated with a hazard ratio of 1.465 (1.290–1.665; P<.001) com-
pared with a reference hazard ratio of 1 for a negative result. On statistical modeling, the best adjustment for pa-
tients with a positive pleural lavage cytology result was a single increase in the T category assigned to the case, up
to a maximum of T4. Correction for differences in survival were obtained in stages IB (P ¼ .315) and IIB
(P ¼ .453), with a degree of correction in stage IIIA (P ¼ .07).
Conclusions: Pleural lavage cytology should be considered in all patients with non–small-cell lung cancer suitable
for resection. A positive result is an independent predictor of adverse survival, and the impact on survival suggests
that it may be appropriate to upstage patients by 1 T category. (J Thorac Cardiovasc Surg 2010;139:1441-6)Pleural lavage cytology (PLC) is the microscopic study of
cells obtained from saline instilled into and retrieved from
the chest cavity (in patients without preoperative pleural ef-
fusion) during surgery for non–small-cell lung cancer. The
solution is aspirated, and cytologic analysis is performed
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The Journal of Thoracic and Carhave been published from Japan as early as 1989,1 and inter-
nationally, an increasing number of centers have adopted
this practice.
The frequency of positive results in the literature
varies according to amount of solution used, timing of
the procedure, and the center, but in general is less
than 10% in the larger published series. Because the pos-
itive pickup rate is low, it is difficult for any single cen-
ter alone to accumulate sufficient patient numbers for
detailed study. As a result, its role as an independent pre-
dictor of prognosis has not been firmly established2,3 and
neither is the lung cancer community certain where to
best place patients with positive results in relation to In-
ternational Union Against Cancer (UICC)/American
Joint Committee on Cancer (AJCC) stage-adjusted
survival.
The aims of this study were to collate individual
patient data from centers that have performed PLC to de-
termine independence as a prognostic marker and to char-
acterize the impact of a positive result on stage-adjusted
survival.METHODS
A literature search was conducted by a professional medical librarian to
identify publications on PLC (the full search strategy is available from Lyn
Edmonds on request). From each publication, the authors were contacted bydiovascular Surgery c Volume 139, Number 6 1441
Abbreviations and Acronyms
AJCC ¼ American Joint Committee on Cancer
PLC ¼ pleural lavage cytology
UICC ¼ International Union Against Cancer
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SE-mail or telephone or in person and invited to contribute data from their
respective centers. Authors who responded were issued a data dictionary,
and submissions were collated electronically in the specified standardized
format. Staging was requested to follow the 6th UICC TNM Classification
of Malignant Disease.4
Statistical Analyses
Continuous variables are expressed as means with standard deviations
or median with interquartile ranges as appropriate to the data distribution.
Nominal and categorical variables are expressed as frequency counts with
percentages (%). Actuarial survival was calculated using Kaplan-Meier
methods, and comparisons were performed using the log-rank test. Cox
proportional hazards regression was used to ascertain the covariates asso-
ciated with survival. Exploratory models were undertaken to determine
the effect of upstaging of patients with positive PLC, including fixed
and variable T-category assignment and stage groupings, compared
with their peers at a higher stage.
Statistical analyses were performed using R 2.6.0 (R core development
team, Vienna, Austria) and Stata 9.2 (StataCorp, College Station, Tex).
There was no funding associated with this project.RESULTS
From 345 abstracts, we identified 31 publications1-3,5-32
from 22 centers/research groups that performed PLC dur-TABLE 1. Demographic and follow-up details
Centre Institution Location Number, n
1 National Cancer
Center Hospital East
Chiba, Japan 2950
2 Osaka Medical Centre
for Cancer and
Cardiovascular Diseases
Osaka, Japan 507
3 Taichung Veterans
General Hospital
Taichung, Taiwan 36
4 The Royal Brompton
Hospital
London, UK 292
5 Hopital European
Georges Pompidou
Paris, France 194
6 Osaka Prefectural Medical
Center for Respiratory
and Allergic Diseases
Osaka, Japan 1522
7 Kurashiki Central Hospital Okayama, Japan 1025
8 Hyogo Cancer Centre Akashi, Japan 1192
9 Cancer Institute Hospital Tokyo, Japan 853
10 Second University of Naples Naples, Italy 107
11 Chest Diseases Hospital Athens, Greece 85
Total 8763
IQR, Interquartile range; PLC, pleural lavage cytology; SD, standard deviation.
1442 The Journal of Thoracic and Cardiovascular Suring surgery for non–small-cell lung cancer. All lead au-
thors from the identified centers or research groups were
contacted by E-mail or telephone or in person. By the
deadline of January 1, 2008, submissions were received in-
ternationally from 11 centers with individual data from
8763 patients. The mean age (standard deviation) of the
cohort was 64 (10) years, with the majority being male
(66%). The demographic and follow-up details from the
11 centers and entire cohort are summarized in Table 1.
The pathologic T, N, and M categories are summarized
in Table 2.
In total, 511 (5.8%) patients were documented with pos-
itive PLC (evaluated on light microscopy), and the staging
characteristics in 477 patients with complete staging infor-
mation were 29 (6.1) in IA, 122 (25.6) in IB, 7 (1.5) in
IIA, 92 (19.3) in IIB, 112 (23.4) in IIIA, 84 (17.6) in IIIB,
and 31 (6.5) in IV, respectively.Survival
At a median follow-up time of 3.3 (1.3–5.8) years, follow-
up was complete in 8213 patients (94%) with 3441 (39%)
deaths. On multivariable Cox regression analysis (Table 3),
positive PLC status was identified as an independent predic-
tor of adverse survival, associated with a hazard ratio of
1.465 (1.290–1.665; P<.001). Increasing age, male gender,
increasing UICC/AJCC staging categories of pT, pN, and M
status were all independent predictors of adverse survival
(P<.001). In addition, despite inclusion in the T categories,
tumor size (P < .001) and breeching of the visceralMean
age (SD)
Males,
n (%)
Positive
PLC, n (%)
Median
follow up, y (IQR)
Deaths,
n (%)
65 (10) 1866 (63) 117 (4.0) 3.0 (1.4–6.1) 982 (33)
63 (9) 363 (72) 73 (14.4) 4.5 (2.1–6.4) 249 (49)
64 (8) 29 (81) 15 (41.7) 1.5 (0.4–5.2) 28 (78)
64 (10) 196 (67) 13 (4.5) 1.25 (0.1–3.3) 94 (32)
62 (12) 140 (72) 24 (12.3) 2.7 (1.3–3.7) 84 (43)
64 (10) 1081 (71) 92 (6.0) 2.3 (1.0–5.5) 839 (55)
67 (10) 627 (61) 45 (4.3) 2.2 (0.8–4.8) 253 (25)
64 (10) 833 (70) 52 (4.3) 4.5 (2.4–6.4) 517 (43)
63 (10) 500 (59) 41 (4.8) 4.4 (2.9–6.2) 272 (32)
65 (9) 97 (91) 31 (29.0) 4.9 (1.9–5.8) 43 (40)
60 (8) 77 (91) 8 (9.4) 3.4 (1.4–4.9) 80 (94)
64 (10) 5809 (66) 511 (5.8) 3.3 (1.3–5.8) 3441 (39)
gery c June 2010
TABLE 3. Multivariable predictors of survival
Covariate
Hazard
ratio
95% confidence
interval P value
Positive lavage cytology 1.465 1.290–1.665 <.001
Age, per year 1.023 1.019–1.027 <.001
Female gender 0.683 0.625–0.746 <.001
pT category
T1 1.000 N/A N/A
T2 1.422 1.277–1.583 <.001
T3 1.340 1.116–1.610 .002
T4 1.511 1.292–1.767 <.001
pN category
N0 1.000 N/A N/A
N1 1.897 1.723–2.088 <.001
N2 3.133 2.864–3.427 <.001
N3 4.758 3.680–6.153 <.001
M1 status 2.169 1.854–2.539 <.001
Size of primary
tumor, cm
1.091 1.069–1.113 <.001
Visceral pleural invasion 1.289 1.183–1.404 <.001
Parietal pleural invasion 1.344 1.150–1.571 <.001
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S(P< .001) and parietal pleura (P< .001) remained stage-
independent predictors of adverse survival.
The overall 1- and 5-year survivals of the 511 patients
who were PLC-positive were 80% and 31%, respectively.
Stage for stage, patients with positive PLC results had poorer
survival compared with their peers with a negative result
(Figure 1, A–C). When overall survival was plotted for stage
groupings I to III, patients with positive PLC result had sim-
ilar overall survival to patients in UICC/AJCC stage III
(Figure 1, D).
Using exploratory statistical modeling, the best adjust-
ment for patients with a positive PLC result was to increase
the T category assigned by a single numerical category
(upstage). This had the effect of upstaging patients into
designated groups and retaining the independent effects of
nodal status on patients who were PLC-positive. The differ-
ences in adjusted survival by increasing the T stage by 1
category for patients who were PLC-positive (up to a maxi-
mum of T4 status) are presented in Figures 2 and 3 for stages
IB, IIB, IIIA, and IIIB. The results were not presented for
stages IA and IIA, as no comparative group remains when
patients in T1 who were PLC-positive are reassigned to
T2. Good correction is visible in stages I to II, and the differ-
ences are somewhat reduced in stage IIIB. No correction is
present in stage IIIB as the T4 designation remains
unaltered.
DISCUSSION
Although a number of studies have reported positive PLC
result as a predictor of poor prognosis, there have been con-
flicting opinions if it is independent to UICC/AJCC stage.2
A principle difficulty in evaluating prognostic independence
on multivariable analyses is the relatively small number ofdiovascular Surgery c Volume 139, Number 6 1443
Time from surgery in years
Pe
rc
e
n
ta
ge
 S
ur
viv
a
l P
ro
ba
bil
ity
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
70
80
90
100
P<0.001
Stage I survival
Time from surgery in years
Pe
rc
e
n
ta
ge
 S
ur
viv
a
l P
ro
ba
bil
ity
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
70
80
90
100
P<0.001
Stage II survival
Time from surgery in years
Pe
rc
en
ta
ge
 S
ur
viv
a
l P
ro
ba
bil
ity
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
70
80
90
100
P<0.001
Stage III survival
Time in years from surgery
Su
rv
iv
a
l p
ro
ba
bil
ity
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
70
80
90
100
P<0.001
Stage I-III versus PLC positive survival
FIGURE 1. Overall survival by stage and pleural lavage cytology (PLC) status. Solid lines are patients with negative PLC; dashed lines are patients with
positive PLC.
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G
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Spatients with a positive result. To address this problem, a col-
laborative effort was undertaken by 11 centers from around the
world contributing individual data from over 8700 patients.
The results of our study confirm the independence of pos-
itive PLC as an adverse prognostic predictor in patients
(without preoperative malignant effusion) deemed suitable
for lung resection for non–small-cell lung cancer. The effect
is the upstaging of patients by 1 T category (up to a maximum
of T4). Although patients with T4 disease had poorer survival
associated with a positive PLC status, this remained better
than the M1a designation of the International Association
for the Study of Lung Cancer proposals for stage grouping
in the 7th edition of TNM in lung cancer.33
PLC is inexpensive and simple to perform and does not
require specialized equipment or facilities for analysis.
Techniques, however, differ from center to center, and there
is a need to standardize this practice internationally, to min-
imize differences in the positive results that may arise from
differences in technique. We recommend 100 mL of saline1444 The Journal of Thoracic and Cardiovascular Surirrigated over the lung surface immediately after thoracot-
omy and prior to lung resection. The saline is aspirated
and the sample sent for cytologic screening for malignant
cells. The UICC recommends that cytologic results of pleu-
ral and peritoneal washings be considered separate to the
classification of isolated tumor cells and micrometastasis.
In addition, identification of patients with positive PLC
results can be recorded with the suffix of (cyþ).34
The effect of upstaging patients with early stage disease
will shift a proportion of patients from stage I to II, the
threshold for consideration of postoperative chemotherapy.
It would be ideal for further trials to be conducted to specif-
ically evaluate the utility of postoperative chemotherapy in
the setting of positive PLC status. In the absence of such
evidence, the implications for the change in stage and the
potential benefits for adjuvant chemotherapy should be
carefully considered.
The inferences from this work were based on the avail-
ability of the submitted data and on the assumption thatgery c June 2010
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Adjusted IIB survival
FIGURE 2. Survival by pleural lavage cytology (PLC) status with adjusted T stage for patients with positive PLC in stage I to II. Solid lines are patients with
negative PLC; dashed lines are patients with positive PLC.
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FIGURE 3. Survival by pleural lavage cytology (PLC) status with adjusted T stage for patients with positive PLC in stage III. Solid lines are patients with
negative PLC; dashed lines are patients with positive PLC.
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G
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Sthe estimates would not be significantly altered if data were
submitted by all centers that published on this topic.
CONCLUSIONS
PLC should be considered in all patients with early stage
lung cancer suitable for resection. A positive result is an in-
dependent predictor of adverse survival and carries a progno-
sis that suggests it may be appropriate to upstage patients by
1 T category.
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